Table 5 Clinical outcomes in patients with and without visual manifestations at diagnosis
Patients with visual manifestations at diagnosis (n = 22) | Patients without visual manifestations at diagnosis (n = 38) | |||
|---|---|---|---|---|
Before TCZ initiation | After TCZ initiation | Before TCZ initiation | After TCZ initiation | |
Follow-up time, median (IQR), years | 0.37 (0.20–0.92) | 0.86 (0.28–1.16) | 0.86 (0.18–1.84) | 0.56 (0.37–1.73) |
Rate of flares per year* | ||||
Rate (95% CI) | 1.2 (0.6, 2.5) | 0.4 (0.1–1.2) | 1.5 (0.9–2.4) | 0.6 (0.3–1.2) |
Rate ratio (95% CI) | 0.3 (0.1–0.8) | 0.4 (0.3–0.7) | ||
p value | 0.021 | 0.003 | ||
Patients with ≥ 1 flare, n (%) | 15 (68.2) | 4 (18.2) | 28 (73.7) | 14 (36.8) |
Patients with ≥ 1 flare with visual manifestations, n (%)† | 9 (40.9) | 2 (9.1) | 5 (13.2) | 1 (2.6) |
Permanent vision loss | 1 (4.5) | 0 | 1 (2.6) | 0 |
AION | 1 (4.5) | 0 | 1 (2.6) | 0 |
CRAO | 0 | 0 | 0 | 0 |
Temporary vision impairment | 9 (40.9) | 2 (9.1) | 5 (13.2) | 1 (2.6) |
Amaurosis fugax | 2 (9.1) | 1 (4.5) | 2 (5.3) | 0 |
Blurred vision | 8 (36.4) | 2 (9.1) | 4 (10.5) | 1 (2.6) |
Diplopia | 1 (4.5) | 0 | 1 (2.6) | 0 |
Total no. of flares | 29 | 9 | 73 | 28 |
Total flares with visual manifestations, n (%)† | 10 (34.4) | 2 (22.2) | 5 (6.8) | 1 (3.6) |
Permanent vision loss | 1 (3.4) | 0 | 1 (1.4) | 0 |
AION | 1 (3.4) | 0 | 1 (1.4) | 0 |
CRAO | 0 | 0 | 0 | 0 |
Temporary vision impairment | 10 (34.4) | 2 (22.2) | 5 (6.8) | 1 (3.6) |
Amaurosis fugax | 2 (6.8) | 1 (11.1) | 2 (2.7) | 0 |
Blurred vision | 9 (31.0) | 2 (22.2) | 4 (5.5) | 1 (3.6) |
Diplopia | 1 (3.4) | 0 | 1 (1.4) | 0 |